Indication intelligence, analysis and sector perception

Gene editing stocks, time to harvest some upside?

August 17, 2018

I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%) 

RegMed Investors’ (RMi): call me crazy if I had all the answers but, I have more than most …

August 16, 2018

Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths   I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric.   I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds! Now I’m asking you to commit: 

Regenerative Medicine Earnings Scorecard - Q2/18 - to date

August 15, 2018

Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies     Thirty-five (35) LPS,  four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies;       The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.